Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy
Doxorubicin (DOX) is one of the most powerful chemotherapy drugs used to treat different kinds of cancer. However, its usage has been limited by typical side effects and drug resistance, particularly cardiotoxicity. According to studies, a more effective and promising method is to conjugate it or en...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Bioengineering |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2306-5354/12/4/430 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850155973445943296 |
|---|---|
| author | Wenhui Xia Martin W. King |
| author_facet | Wenhui Xia Martin W. King |
| author_sort | Wenhui Xia |
| collection | DOAJ |
| description | Doxorubicin (DOX) is one of the most powerful chemotherapy drugs used to treat different kinds of cancer. However, its usage has been limited by typical side effects and drug resistance, particularly cardiotoxicity. According to studies, a more effective and promising method is to conjugate it or entrap it in biocompatible nanoparticles. Compared to free DOX and traditional formulations, nanoparticles using specific processes or techniques can improve drug stability, minimize premature release at untargeted locations, and lower systemic toxicity. This review explains how various nanocarriers target the tumor to improve therapeutic efficacy while reducing the negative effects of DOX. |
| format | Article |
| id | doaj-art-a335ec8a0a2647ad96731c312b7dcf3a |
| institution | OA Journals |
| issn | 2306-5354 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Bioengineering |
| spelling | doaj-art-a335ec8a0a2647ad96731c312b7dcf3a2025-08-20T02:24:43ZengMDPI AGBioengineering2306-53542025-04-0112443010.3390/bioengineering12040430Advances in Targeted Delivery of Doxorubicin for Cancer ChemotherapyWenhui Xia0Martin W. King1Wilson College of Textiles, North Carolina State University, Raleigh, NC 27606, USAWilson College of Textiles, North Carolina State University, Raleigh, NC 27606, USADoxorubicin (DOX) is one of the most powerful chemotherapy drugs used to treat different kinds of cancer. However, its usage has been limited by typical side effects and drug resistance, particularly cardiotoxicity. According to studies, a more effective and promising method is to conjugate it or entrap it in biocompatible nanoparticles. Compared to free DOX and traditional formulations, nanoparticles using specific processes or techniques can improve drug stability, minimize premature release at untargeted locations, and lower systemic toxicity. This review explains how various nanocarriers target the tumor to improve therapeutic efficacy while reducing the negative effects of DOX.https://www.mdpi.com/2306-5354/12/4/430drug deliverycancernanotechnologycarriertargeted therapy |
| spellingShingle | Wenhui Xia Martin W. King Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy Bioengineering drug delivery cancer nanotechnology carrier targeted therapy |
| title | Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy |
| title_full | Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy |
| title_fullStr | Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy |
| title_full_unstemmed | Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy |
| title_short | Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy |
| title_sort | advances in targeted delivery of doxorubicin for cancer chemotherapy |
| topic | drug delivery cancer nanotechnology carrier targeted therapy |
| url | https://www.mdpi.com/2306-5354/12/4/430 |
| work_keys_str_mv | AT wenhuixia advancesintargeteddeliveryofdoxorubicinforcancerchemotherapy AT martinwking advancesintargeteddeliveryofdoxorubicinforcancerchemotherapy |